Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03787368 · ClinicalTrials.gov registry record · Phase 1
End-stage Renal Disease (ESRD) Pilot Study
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT03787368 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 55 participants.
The verdict
NCT03787368, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety of two different doses of a drug called BAY1213790 and how well it is tolerated in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Approximately 40, with up to 60 study patients will take part in the study.
Interventions
- DRUG BAY1213790
- DRUG 0.9% sodium chloride solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2021-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03787368
The ClinicalTrials.gov registry entry for NCT03787368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BAY1213790 is the first listed.
NCT03787368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03787368 about?
NCT03787368 is a clinical study titled "End-stage Renal Disease (ESRD) Pilot Study". The purpose of this study is to investigate the safety of two different doses of a drug called BAY1213790 and how well it is tolerated in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Approximately 40, with up to 60 study patients will take part in the study.
What is the current status of trial NCT03787368?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2019-01-31. Estimated completion is 2021-09-15.
What interventions are being tested in trial NCT03787368?
The interventions under investigation include: BAY1213790 (DRUG), 0.9% sodium chloride solution (DRUG).
Who is sponsoring clinical trial NCT03787368?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.